Medical therapy to control inflammation may influence IOP outcome in SLT cases
Sep 1, 2006
By:
Cheryl Guttman
|
San Francisco—Selective laser trabeculoplasty (SLT) is a major advance in the management of glaucoma because it safely and effectively lowers IOP without damaging or disrupting the trabecular beams.
Treatment guidelines still needed, however; approach does not work for everyone
Feb 1, 2007
By:
Ed Edelson
|
New York—The idea of using selective laser trabeculoplasty (SLT) for steroid-induced glaucoma originated with a patient's stubborn resistance to surgery, according to Janet P. Serle, MD.
Added benefits include fewer side effects, less expense; adherence not an issue
Jan 15, 2007
By:
Lynda Charters
|
Las Vegas—Selective laser trabeculoplasty (SLT) is comparable to medical treatment as the initial therapy for open-angle glaucoma (OAG) or ocular hypertension, according to results of a study reported by L. Jay Katz, MD, and colleagues here at the American Academy of Ophthalmology annual meeting.
Prospective study finds similar safety and efficacy when comparing SLT with medical treatment
Sep 1, 2006
By:
Cheryl Guttman
|
London, Ontario—During at least the first 12 months after treatment initiation, selective laser trabeculoplasty (SLT) and latanoprost 0.005% (Xalatan, Pfizer) are associated with equivalent efficacy and safety profiles when used as primary therapy for newly diagnosed open-angle glaucoma or ocular hypertension, according to the results of a prospective, multicenter, parallel comparison, clinical trial conducted by researchers at Ivey Eye Institute, University of Western Ontario, London.
